Brief: Allovir Q3 EPS USD -0.39
02/11/2023 11:00
Nov 02 (Reuters) - Allovir Q3 net income USD -44.272 million. * Q3 operating income USD -46.961 million * Q3 operating expenses USD 46.961 million
Recent news on Kalaris Therapeutics
See all newsKalaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Kalaris Therapeutics Q2 net loss narrows on lower administrative costs
Kalaris Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Kalaris Therapeutics posts smaller-than-expected Q1 net loss
Brief: Kalaris Therapeutics Inc Q1 Operating Income USD -11.833 Million